Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Eyelash Growth From Application of Bimatoprost in Gel Suspension to the Base of the Eyelashes
This study has been completed.
Sponsored by: University of Miami
Information provided by: University of Miami
ClinicalTrials.gov Identifier: NCT00773136
  Purpose

Objective: To determine if Lumigan (bimatoprost) causes increased lash length when used in gel suspension applied to the base of the eyelashes. Methods: Subjects recruited from the Bascom Palmer Eye Institute were screened and those who met inclusion criteria were enrolled. Each participant received two vials of gel suspension, which contained bimatoprost and normal saline, respectively, each mixed 1:1 with GonakTM gel and labeled "right eye" and "left eye" according to randomization. The suspension was applied to the eyelashes every evening on the designated eye for 6 weeks. Lash length was measured with a caliper at enrollment, at weekly intervals during the study and at 1 and 3 months after study completion. Visual acuity, ocular symptoms, intraocular pressure and photographs were documented at these same intervals. Results: The average eyelash growth in the Lumigan group was 2.01mm (vs. control average of 1.13mm) which was a statistically significant difference (p=0.009). The average intraocular pressure decreased equally in both groups (2.14 mmHg). No change in visual acuity or iris discoloration was noted in any of the subjects. Discussion: Our data showed an increase in eyelash length with use of Lumigan in gel suspension, suggesting that it may have eyelash lengthening properties.


Condition Intervention
Eyelash Lengthening
Drug: Bimatoprost mixed with Gonak into a gel suspension

Drug Information available for: Bimatoprost
U.S. FDA Resources
Study Type: Interventional
Study Design: Parallel Assignment
Official Title: Effect of Bimatoprost (Lumigan) in Gel Suspension Applied to the Eyelashes on Eyelash Growth

Further study details as provided by University of Miami:

Study Start Date: February 2008
Study Completion Date: July 2008
Primary Completion Date: July 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Lumigan Suspension
Each subject was given two suspensions, one mixed with Lumigan and one mixed with normal saline. They were instructed to use the Lumigan suspension to a pre-determined eyelash (prepared prior to study enrollment in double blind fashion).
Drug: Bimatoprost mixed with Gonak into a gel suspension

  Eligibility

Ages Eligible for Study:   20 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Age greater than 20 and less than 90 and patients who have previously used and are comfortable with applying mascara.

Exclusion Criteria:

  • History of glaucoma, uveitis, pregnancy, allergic reaction to prostaglandins or the gel suspension, alopecia, and previous usage of other eyelash growth enhancement.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00773136

Locations
United States, Florida
University of Miami, Bascom Palmer Eye Institute
Miami, Florida, United States, 33136
Sponsors and Collaborators
University of Miami
  More Information

Responsible Party: University of Miami, Bascom Palmer Eye Institute ( Wendy W. Lee )
Study ID Numbers: 20070706
Study First Received: October 15, 2008
Last Updated: October 15, 2008
ClinicalTrials.gov Identifier: NCT00773136  
Health Authority: United States: Institutional Review Board

Keywords provided by University of Miami:
Bimatoprost
Eyelash lengthening
Prostaglandin Analogs
Cosmetics

Study placed in the following topic categories:
Bimatoprost

Additional relevant MeSH terms:
Therapeutic Uses
Cardiovascular Agents
Antihypertensive Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 14, 2009